0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Antileukotrienes in the Treatment of Asthma

Paul M. O'Byrne, MB; Elliot Israel, MD; and Jeffrey M. Drazen, MD
[+] Article and Author Information

From McMaster University, Hamilton, Ontario, Canada; and Harvard Medical School, Boston, Massachusetts. Requests for Reprints: Paul M. O'Byrne, MB, Asthma Research Group, Department of Medicine, Division of Respirology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada. Current Author Addresses: Dr. O'Byrne: Asthma Research Group, Department of Medicine, Division of Respirology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1997;127(6):472-480. doi:10.7326/0003-4819-127-6-199709150-00009
Text Size: A A A

Purpose: To review the activity in clinical models, the efficacy, and the safety of antileukotrienes as a new class of antiasthma treatment.

Data Sources: English-language trials identified from the archival literature, including the MEDLINE database, through 1996; bibliographic references; and textbooks.

Study Selection: Reports from placebo-controlled, double-blind, randomized trials were selected.

Data Extraction: Study designs and results were extracted from the clinical trial reports. Statistical evaluation of combined results was not attempted.

Data Synthesis: The various classes of antileukotrienes have shown activity in clinical models of asthma, including exercise-induced, cold air hyperventilation-induced, allergen-induced, and aspirin-induced bronchoconstriction. In addition, the antileukotrienes partially reverse spontaneous bronchoconstriction in asthmatic persons, an effect additive to that of inhaled β2-agonists. Clinical trials of the antileukotrienes have shown clinical benefit, as measured by reductions in asthma symptom scores, improvements in air flow obstruction, and reductions in the rescue use of inhaled β2-agonists. Some, but not all, of the antileukotrienes have been shown to cause liver microsomal activation with increases in hepatic aminotransferase levels.

Conclusions: Antileukotrienes are an important new therapy for asthma. Inhibition of leukotriene synthesis or action has a beneficial effect in the treatment of both induced and spontaneous asthma. These results show that leukotrienes are important mediators of the asthmatic response. In addition, encouraging results have been obtained from clinical trials of antileukotrienes; however, these results do not yet provide guidelines for the optimal clinical use of antileukotrienes in asthma treatment. Such recommendations await the results of further studies.

Figures

Grahic Jump Location
Figure 1.
The 5-lipoxygenase (5-LO) pathway of arachidonic acid (AA) metabolism, showing the other enzymes (5-lipoxygenase activating protein [FLAP] and leukotriene C4 [LTC4] synthetase) necessary for the production of the cysteinyl leukotrienes.1444444

In addition, 5-LO activating protein antagonists, such as BAYx1005 and MK-886; 5-LO inhibitors, such as zileuton; and cysteinyl leukotriene receptor type 1 (CysL T ) receptor antagonists, such as zafirlukast, inhibit the production or action of the cysteinylleukotrienes. 5-HPETE = 5-hydroperoxyeicosatetraenoic acid; LTA ( ) = leukotriene A ; LTD = leukotriene D ; LTE = leukotriene E .

Grahic Jump Location
Grahic Jump Location
Figure 2.
The effect of a selective cysteinyl leukotriene receptor type 1 (CysLT1) receptor antagonist, MK-571, on the percentage decrease from baseline in the FEV1 after exercise in asthmatic patients.1[52]

Pretreatment with MK-571 markedly attenuated the decrease in FEV after exercise. Reproduced from Impens and colleagues with permission.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Percentage of patients who required corticosteroid treatment for exacerbations of asthma after receiving zileuton, 400 mg or 600 mg four times daily, or placebo.1111P[106]

Groups are stratified by FEV as a percentage of predicted value at study entry. A total of 111 patients had an FEV greater than 70%, 187 had an FEV of 50% to 70%, and 103 had an FEV ( ) less than 50%. *  < 0.05 for comparison with placebo. Reproduced from Israel and colleagues with permission.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)